Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil(R) Revenue
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil(R) Revenue GlobeNewswire November 24, 2025 NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief […]